Variability of Circulating Tumor DNA Levels in Plasma Samples From Patients With Advanced Non–Small-Cell Lung Cancer in the Absence of Treatment
Open Access
- 1 October 2025
- journal article
- Published by American Society of Clinical Oncology (ASCO) in JCO Precision Oncology
- Vol. 9 (9) , e2500287
Abstract
PURPOSE: Quantifying changes in circulating tumor DNA (ctDNA) during treatment can rapidly identify patients responding to therapy, but accurate interpretation requires an understanding of variability in ctDNA levels in the absence of treatment. This analysis of 360 patients with advanced epidermal growth factor receptor ( EGFR )–mutant non–small-cell lung cancer (NSCLC) characterized ctDNA level changes in paired pretreatment samples and evaluated factors associated with variability. METHODS: Screening and cycle 1, day 1 (C1D1) pretreatment samples from 132 previously untreated and 228 previously treated patients in the FLAURA and AURA3 trials, respectively, had ctDNA quantified using next-generation sequencing (Guardant360/GuardantOMNI NGS panel; mean variant allele frequency [VAF] or EGFR -mutant VAF) and droplet digital polymerase chain reaction (ddPCR, Biodesix) EGFR assays. RESULTS: In FLAURA and AURA3, ≥20% reductions in ctDNA levels (panel mean VAF) from screening to C1D1 occurred in 31/132 (23.5%) and 43/228 (18.9%) patients with paired pretreatment plasma samples, respectively, including ≥50% reductions in 12 (9.1%) and 23 (10.1%) patients, and 100% reductions (ctDNA clearance) in 0 and 5 (2.2%) patients. Background variability was not fully accounted for by intra-NGS or NGS-ddPCR technical variability or other potential sources of variability; larger changes were associated with low VAF and low cell-free DNA (cfDNA) input. CONCLUSION: Intrapatient ctDNA variability over time in EGFR- mutant advanced NSCLC includes changes that may confound interpretation of treatment activity, depending on the magnitude of change used to indicate molecular response. These findings demonstrate that evaluation of on-treatment changes must account for potential background variability, including technical variability because of factors such as cfDNA input level and tumor-related VAF, and that baseline samples should be obtained as close as possible to treatment initiation to minimize the impact of background variability.Keywords
This publication has 51 references indexed in Scilit:
- Osimertinib treatment based on plasma T790M monitoring in patients with EGFR-mutant non-small-cell lung cancer (NSCLC): EORTC Lung Cancer Group 1613 APPLE phase II randomized clinical trialAnnals of Oncology, 2023
- Clinical utility of circulating tumor DNA sequencing with a large panel: a National Center for Precision Medicine (PRISM) studyAnnals of Oncology, 2023
- Early circulating tumorDNAdynamics as a pan‐tumor biomarker for long‐term clinical outcome in patients treated with durvalumab and tremelimumabMolecular Oncology, 2022
- ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working GroupAnnals of Oncology, 2022
- Circulating tumor DNA as a biomarker for monitoring early treatment responses of patients with advanced lung adenocarcinoma receiving immune checkpoint inhibitorsMolecular Oncology, 2021
- International liquid biopsy standardization alliance white paperCritical Reviews in Oncology/Hematology, 2020
- Minimum Technical Data Elements for Liquid Biopsy Data Submitted to Public DatabasesClinical Pharmacology & Therapeutics, 2020
- Day-to-day and within-day biological variation of cell-free DNAEBioMedicine, 2019
- Intra‐individual variation of circulating tumour DNA in lung cancer patientsMolecular Oncology, 2019
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009